Drug intelligence / Profile preview

OvcaVax

Development stage: Preclinical
Lead developer: OncBioMune Pharmaceuticals
Modality: Vaccines & Immunotherapeutics
Administration: Intradermal

Overview

**OvcaVax** is an investigational therapeutic ovarian cancer vaccine developed by OncBioMune. It comprises cancer antigen 125, interleukin-2, and granulocyte-macrophage colony-stimulating factor, and is intended to induce an immune response against CA-125-expressing ovarian tumor cells while cytokine components stimulate antitumor immune activity. In 2017, OncBioMune announced plans to initiate a small adjuvant-setting clinical study in ovarian cancer following surgery. ([synapse.patsnap.com](https://synapse.patsnap.com/drug/887ffe1c1fc54520b8f1ce345acb6af4))

Other names: OvcaVax

Targets

CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)IL-2R (Interleukin-2/interleukin-15 receptor complex)MUC16 (Mucin-16)

Beyond the preview

Go deeper on OvcaVax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OvcaVax.

Explore the full profile